Prosight Management, LP - Q3 2019 holdings

$180 Million is the total value of Prosight Management, LP's 34 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 43.6% .

 Value Shares↓ Weighting
ZBH SellZIMMER BIOMET HOLDINGS INC$17,571,000
-9.3%
128,000
-22.2%
9.75%
-0.3%
BMY SellBRISTOL-MYERS SQUIBB CO$15,461,000
-16.9%
304,900
-25.7%
8.58%
-8.6%
KURA BuyKURA ONCOLOGY INC$13,473,000
-21.2%
888,152
+2.3%
7.47%
-13.2%
QURE BuyUNIQURE NV$12,949,000
+38.1%
328,978
+174.1%
7.18%
+51.9%
UTHR BuyUNITED THERAPEUTICS CORP$10,602,000
+1480.0%
132,937
+1445.8%
5.88%
+1639.9%
HNGR SellHANGER INC$8,050,000
-14.5%
395,000
-19.7%
4.46%
-6.0%
URGN BuyUROGEN PHARMA LTD$7,754,000
-17.3%
325,385
+24.7%
4.30%
-9.0%
ARNA SellARENA PHARMACEUTICALS INC$7,467,000
-22.5%
163,133
-0.7%
4.14%
-14.7%
CNC BuyCENTENE CORP$7,138,000
+7.6%
165,000
+30.4%
3.96%
+18.4%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$6,300,000
-35.8%
346,149
-13.5%
3.50%
-29.3%
ACIU BuyAC IMMUNE SA$6,180,000
+97.4%
1,248,453
+121.4%
3.43%
+117.2%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$6,063,000
+38.3%
89,952
+75.7%
3.36%
+52.1%
SBBP SellSTRONGBRIDGE BIOPHARMA PLC$6,011,000
-24.6%
2,515,072
-1.3%
3.33%
-17.1%
MGTX NewMEIRAGTX HOLDINGS PLC$5,393,000338,096
+100.0%
2.99%
ALBO SellALBIREO PHARMA INC$5,050,000
-38.2%
252,500
-0.3%
2.80%
-32.0%
RETA SellREATA PHARMACEUTICALS INC-Acl a$5,025,000
-57.4%
62,591
-49.9%
2.79%
-53.1%
ALDX BuyALDEYRA THERAPEUTICS INC$4,165,000
-0.5%
790,228
+13.2%
2.31%
+9.4%
RCM NewR1 RCM INC$3,652,000408,958
+100.0%
2.03%
HUM NewHUMANA INC$3,068,00012,000
+100.0%
1.70%
ABBV NewABBVIE INC$2,953,00039,000
+100.0%
1.64%
FIXX SellHOMOLOGY MEDICINES INC$2,775,000
-61.6%
153,303
-58.5%
1.54%
-57.7%
CBIO BuyCATALYST BIOSCIENCES INC$2,741,000
-32.0%
558,159
+2.0%
1.52%
-25.2%
GH NewGUARDANT HEALTH INC$2,662,00041,700
+100.0%
1.48%
ARQL BuyARQULE INC$2,616,000
+184.0%
364,797
+336.0%
1.45%
+212.7%
ADMA BuyADMA BIOLOGICS INC$2,440,000
+239.4%
548,409
+195.3%
1.35%
+272.7%
TLGT SellTELIGENT INC$2,323,000
+24.2%
2,446,043
-17.6%
1.29%
+36.7%
CLVS BuyCLOVIS ONCOLOGY INC$2,309,000
-65.5%
587,626
+30.6%
1.28%
-62.0%
PSNL BuyPERSONALIS INC$1,691,000
+10.3%
115,214
+104.1%
0.94%
+21.3%
CI SellCIGNA CORP$1,670,000
-66.1%
11,000
-64.8%
0.93%
-62.7%
MTEM BuyMOLECULAR TEMPLATES INC$1,470,000
-11.0%
222,994
+12.8%
0.82%
-2.0%
NewREATA PHARMACEUTICALS INCcall$988,00012,300
+100.0%
0.55%
UROV SellUROVANT SCIENCES LTD$972,000
-13.8%
102,657
-28.0%
0.54%
-5.3%
SRRA SellSIERRA ONCOLOGY INC$924,000
-38.5%
2,366,707
-11.7%
0.51%
-32.2%
MLND SellMILLENDO THERAPEUTICS INC$370,000
-56.7%
52,051
-29.5%
0.20%
-52.4%
AQXP ExitAQUINOX PHARMACEUTICALS INC$0-3,637
-100.0%
-0.01%
KZR ExitKEZAR LIFE SCIENCES INC$0-34,224
-100.0%
-0.13%
CDTX ExitCIDARA THERAPEUTICS INC$0-358,963
-100.0%
-0.30%
NVRO ExitNEVRO CORP$0-11,000
-100.0%
-0.36%
PRSC ExitPROVIDENCE SVC CORP$0-14,677
-100.0%
-0.42%
EOLS ExitEVOLUS INC$0-112,590
-100.0%
-0.83%
ExitEXACT SCIENCES CORPput$0-14,100
-100.0%
-0.84%
ASGN ExitASGN INC$0-30,000
-100.0%
-0.92%
WCG ExitWELLCARE HEALTH PLANS INC$0-6,500
-100.0%
-0.93%
ASMB ExitASSEMBLY BIOSCIENCES INC$0-200,000
-100.0%
-1.36%
ExitINTEC PHARMA LTD JERUSALEM$0-815,789
-100.0%
-1.78%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALDEYRA THERAPEUTICS INC19Q2 20236.2%
ALBIREO PHARMA INC18Q4 20229.2%
MEIRAGTX HOLDINGS PLC18Q3 20236.3%
KEZAR LIFE SCIENCES INC17Q3 20238.2%
ARENA PHARMACEUTICALS INC16Q4 20218.2%
IOVANCE BIOTHERAPEUTICS INC16Q1 20227.7%
CENTENE CORP DEL16Q3 20235.3%
CUE BIOPHARMA INC14Q1 20235.6%
PROTHENA CORP PLC13Q3 202313.6%
ZIMMER BIOMET HOLDINGS INC13Q3 20219.8%

View Prosight Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Prosight Management, LP Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXICURE, INC.February 14, 20222,426,5082.2%
Aldeyra Therapeutics, Inc.February 12, 2021908,4882.3%
Teligent, Inc.February 14, 20201,484,5272.8%
Cidara Therapeutics, Inc.February 14, 2019245,7640.9%
Eiger BioPharmaceuticals, Inc.Sold outFebruary 14, 201900.0%
Millendo Therapeutics, Inc.February 14, 2019256,7392.0%
OvaScience, Inc.October 26, 20181,991,1005.6%
CHIMERIX INCFebruary 13, 20181,478,5193.1%
Harvard Apparatus Regenerative Technology, Inc.February 12, 2016184,3601.4%

View Prosight Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-02
13F-HR2023-11-14
SC 13G2023-09-01

View Prosight Management, LP's complete filings history.

Compare quarters

Export Prosight Management, LP's holdings